Back to top
more

Auris Medical Holding AG (EARS)

(Delayed Data from NSDQ)

$4.82 USD

4.82
114,107

-0.32 (-6.23%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.80 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Altamira Therapeutics Ltd. [EARS]

Reports for Purchase

Showing records 1 - 20 ( 26 total )

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 1

09/18/2020

Company Report

Pages: 5

A nasal spray to help protect against COVID-19

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 2

04/21/2020

Company Report

Pages: 6

AM-201 data expected in early May

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 3

10/15/2019

Company Report

Pages: 5

Interim AM-201 data

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 4

08/20/2019

Company Report

Pages: 6

AM-201 proof of concept data is weeks away

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 5

06/04/2019

Company Report

Pages: 5

Data coming in second half

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 6

03/21/2019

Company Report

Pages: 7

Full-year results and near-term trial initiations

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 7

11/19/2018

Company Report

Pages: 6

Q318 results and business updates

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 8

11/01/2018

Company Report

Pages: 17

Initiation of coverage : Treating vertigo

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 9

09/07/2018

Company Report

Pages: 4

We are dropping coverage of EARS shares to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 10

02/27/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for EARS

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 11

11/29/2017

Industry Report

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 12

11/29/2017

Company Report

Pages: 4

We are placing shares of EARS Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 13

10/02/2017

Industry Report

Pages: 19

Healthcare: Fourth Quarter 2017 Preview Note

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 50.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 14

09/14/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 15

09/14/2017

Company Report

Pages: 15

AM-125 Highlighted at Symposium on Vertigo Therapies

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 50.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 16

08/11/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 17

08/11/2017

Company Report

Pages: 8

All Development Programs On Track; Pivotal Trial Data By YE?17

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 18

07/07/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 19

07/06/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Altamira Therapeutics Ltd.

Industry: Medical - Drugs

Record: 20

07/06/2017

Company Report

Pages: 6

First of Two AM-111''s Phase 3s Are Enrolled; Reiterate $4.50 PT

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party
// eof